Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Allergy TherapeuticsLSE:AGY +8.82% EBIT per Share is £-0.01 as of Dec. 2025. The stock has 7 warning signs investors should review. Among 811 Drug Manufacturers companies, Allergy Therapeutics ranks better than 79.9% on this metric.
Allergy Therapeutics's EBIT per Share for the
six
months ended in Dec. 2025 was £-0.00.
Its EBIT per Share for the trailing twelve months (TTM) ended in Dec. 2025 was £-0.01.
During the past 3 years, the average EBIT per Share Growth Rate was 31.90% per year.
Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the EBIT per Share growth rate using EBIT per Share data.
The historical rank and industry rank for Allergy Therapeutics's EBIT per Share or its related term are showing as below:
LSE:AGY'
s 3-Year EBIT Growth Rate Range Over the Past 10 Years
Min: -81.1 Med: -30.7 Max: 41.7
Current: 31.9
During the past 13 years, the highest 3-Year average EBIT per Share Growth Rate of Allergy Therapeutics was 41.70% per year. The lowest was -81.10% per year. And the median was -30.70% per year.
LSE:AGY's 3-Year EBIT Growth Rate is ranked better than 79.9% of 811
companies
in the Drug Manufacturers industry
Industry Median: 7.5
vs LSE:AGY: 31.90
Allergy Therapeutics (LSE:AGY) EBIT per Share Explanation
EBIT is a company's earnings before interest and tax expenses are deducted. It measures a company's profit generates from operating, ignoring tax burden and capital structure. As the tax expense are not deducted, EBIT is helpful when comparing companies in the same industry but with different tax situations. Also, the interest expense are included in EBIT, making it useful to compare companies that have high interest expenses due to large amount of debt.
Allergy Therapeutics EBIT per Share Related Terms
Allergy Therapeutics EBIT per Share Historical Data
* Premium members only.
The historical data trend for Allergy Therapeutics's EBIT per Share can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
EBIT per Share for the trailing twelve months (TTM) ended in Dec. 2025 adds up the semi-annually data reported by the company within the most recent 12 months, which was £-0.01
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Allergy Therapeutics (LSE:AGY) has a EBIT per Share of £-0.01 as of Dec. 2025. EBIT per Share is the amount of Earnings Before Interest and Taxes per outstanding share of the company's stock. View historical data on Allergy Therapeutics and its competitors. According to the industry distribution chart, Allergy Therapeutics ranks #163 out of 811 companies in the Drug Manufacturers industry, placing it in the top 20.1%.
Is Allergy Therapeutics' EBIT per Share too high?
Allergy Therapeutics' current EBIT per Share is £-0.01. Based on the distribution chart, Allergy Therapeutics ranks #163 out of 811 companies in the Drug Manufacturers industry, which is in the top quartile — a strong position relative to peers.
How does Allergy Therapeutics' EBIT per Share compare to ZTS and UTHR?
According to the Drug Manufacturers industry distribution chart, Allergy Therapeutics ranks #163 out of 811 companies for EBIT per Share. This places Allergy Therapeutics in the top 20% of its industry — outperforming the majority of peers. The industry median EBIT per Share is 7.50. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EBIT per Share for a Drug Manufacturers company?
The median EBIT per Share among Drug Manufacturers companies is 7.50, based on 811 companies in the industry. Companies in the top quartile (top 25%) have a EBIT per Share significantly above this median, while those in the bottom quartile fall well below. However, EBIT per Share should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EBIT per Share mean?
A high EBIT per Share can signal that a stock is expensive relative to its fundamentals. EBIT per Share is the amount of Earnings Before Interest and Taxes per outstanding share of the company's stock. View historical data on Allergy Therapeutics and its competitors. For the Drug Manufacturers industry, the median EBIT per Share is 7.50 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Allergy Therapeutics's current EBIT per Share is £-0.01. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Allergy Therapeutics stock overvalued right now?
Based on GuruFocus' analysis, Allergy Therapeutics (LSE:AGY) is currently considered Significantly Overvalued. The stock's GF Value™ is £0.03, compared to a current price of £0.07 — trading 146.7% above its estimated fair value. The current EBIT per Share is £-0.01. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EBIT per Share calculated?
EBIT per Share is calculated from a company's financial statements. For Allergy Therapeutics (LSE:AGY), the current EBIT per Share is £-0.01 as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Allergy Therapeutics plc is an international biotechnology group focused on the diagnosis and treatment of allergic disorders through immunotherapies that target the underlying cause of disease. Its portfolio includes Pollinex, Pollinex Quattro, Acarovac, Tyrosine S/TU, Venomil, Oralvac and other allergy immunotherapy products, supported by R&D programmes such as Grass MATA MPL and VLP Peanut. The Group operates in a single class of business, being the manufacture and sale of allergy-related medicines, and maintains centralised manufacturing and research and development capabilities in the UK. Its geographical presence covers Central Europe (Germany, Austria, Switzerland and the Netherlands), Southern Europe (Spain and Italy) and the Rest of the World (including the UK).
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
LSE:AGY has been successfully added to your 
